RxDoctor Payments Data

Avery Nolen, MD

Family Medicine · Mansfield, TXNPI 1306281423

Payments from drug & device makers

$6,620in general payments, 2019–2025

Across 338 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$817
  • AstraZeneca$685
  • Lilly USA, LLC$677
  • GSK$657
  • Novo Nordisk$609
  • AbbVie$602
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,57599%
  • Education$60%
  • Entertainment$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,620 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$68,636
Medicare patients
207
Services billed
767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$88,755
EliquisApixaban56$58,112
JardianceEmpagliflozin33$44,727
TrulicityDulaglutide25$31,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$25,134
JanuviaSitagliptin Phosphate27$21,732
MounjaroTirzepatide15$20,270
FarxigaDapagliflozin Propanediol15$13,598
Testosterone12$7,466
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,936
Dexlansoprazole DrDexlansoprazole12$3,452
Atorvastatin Calcium374$3,186
Albuterol Sulfate HfaAlbuterol Sulfate65$2,225
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,168
Amlodipine Besylate318$1,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$609$88,75576 claims
PfizerEliquis$817$58,11256 claims
Lilly USA, LLCTrulicity, Mounjaro$677$51,28340 claims
Boehringer IngelheimJardiance$207$44,72733 claims
GSKTrelegy Ellipta$657$25,13425 claims
MerckJanuvia$85$21,73227 claims
AstraZenecaFarxiga$685$13,59815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,638136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Mansfield

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →